Adverse events at 3 to 12 months' · eyes with acute endophthalmitis following an intraocular procedure (e.g. surgery, intravitreous injection)
Combined steroid and antibiotic therapy showed no clear difference in adverse events at 3 to 12 months' compared with antibiotics alone (low certainty).
1 finding from 1 review
Adverse events at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab every 4 weeks showed no clear difference in adverse events at ≥ 12 months compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab weekly showed no clear difference in adverse events at ≥ 12 months compared with placebo + 52‐week taper (moderate certainty).
1 finding from 1 review
Adverse events at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab weekly showed no clear difference in adverse events at ≥ 12 months compared with placebo + 26‐week taper (moderate certainty).
1 finding from 1 review
Adverse events at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab every other week showed no clear difference in adverse events at ≥ 12 months compared with placebo + 52‐week taper (moderate certainty).
1 finding from 1 review
Adverse events at ≥ 12 months · adults aged over 50 years with giant cell arteritis
Tocilizumab every other week showed no clear difference in adverse events at ≥ 12 months compared with placebo + 26‐week taper (moderate certainty).
1 finding from 1 review
Serious adverse events at 6 or 12 months · adults and children with strabismus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events 12 months postintervention · adults with refractory glaucoma
1 finding from 1 review
Intervention not reported
Adverse events 12 months postintervention · adults with refractory glaucoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse events 12 months postintervention · adults with refractory glaucoma
1 finding from 1 review
Adverse events 12 months postintervention · adults with refractory glaucoma
1 finding from 1 review
Incidence of adverse events at 3 months of · people with meibomian gland dysfunction
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Non‐serious adverse events at 6 or 12 months · adults and children with strabismus
1 finding from 1 review
Adverse events (ocular problems) · people with age‐related cataract
Routine preoperative medical testing showed no clear difference in ocular adverse events up to 2 months after surgery compared with selective or no testing (moderate certainty).
1 finding from 1 review
Intervention not reported
Ocular adverse events: endophthalmitis at 6 months · participants with CRVO macular oedema of duration less than 9 months (mean < 3 months) and no prior treatment
1 finding from 1 review
Medical adverse events up to 2 months after surgery · people with age‐related cataract
Routine preoperative medical testing showed no clear difference in medical adverse events up to 2 months after surgery compared with selective or no testing (high certainty).
1 finding from 1 review
Proportion of participants with adverse events with a probable causal link with the study interventions at six months · adults undergoing cataract surgery with IOL implantation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: AMD progression at 12 months Defined as increased drusen volume or onset of advanced AMD. Conversion to exudative AMD at 12 months Assessed by clinical examination and retinal optical coherence tomography. · people with non‐exudative AMD (AREDS 2 to 4)
Photobiomodulation treatment showed no clear difference in adverse events: AMD progression at 12 months Defined as increased… compared with sham or no treatment (low certainty).
1 finding from 1 review
RR 0.79 [0.41, 1.53]
Studies not reported
Low